Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Commentary|Articles|September 11, 2025
FLAURA-2 and HARMONi Trial Readouts Reinforce Importance of ‘Divide and Conquer’ Approach to Lung Cancer Care at WCLC 2025
Author(s)Courtney Flaherty
Fact checked by: Ashley Chan
Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.
Advertisement
Advertisement
The
Related to this article
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Advertisement
Advertisement